Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Class A common stock, par value $0.001 per share
Symbol
IMRX on Nasdaq
Shares outstanding
66,027,379
Price per share
$5.22
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
31,745,075
Total reported value
$208,863,999
% of total 13F portfolios
0%
Share change
+3,001,086
Value change
+$18,230,258
Number of holders
86
Price from insider filings
$5.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 14% $71,526,603 8,787,052 FMR LLC 30 Sep 2025
Zeskind Benjamin J. 6.6% -48% $28,674,370 +$2,498,025 4,357,807 +9.5% BENJAMIN J. ZESKIND 31 Dec 2025
HBM Healthcare Investments (Cayman) Ltd. 5.7% $29,680,915 3,646,304 HBM Healthcare Investments (Cayman) Ltd. 26 Sep 2025
Empery Asset Management, LP 5% -43% $20,154,805 -$12,015,476 3,250,775 -37% Empery Asset Management, LP 31 Dec 2025

As of 31 Dec 2025, 86 institutional investors reported holding 31,745,075 shares of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX). This represents 48% of the company’s total 66,027,379 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) together control 44% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 9,685,495 +10% 0% $63,730,557
Sanofi 4.1% 2,708,559 0% 5.7% $17,822,318
Empery Asset Management, LP 4.1% 2,674,950 0% 16% $17,601,171
VANGUARD GROUP INC 3.9% 2,568,293 +6.3% 0% $16,899,368
STATE STREET CORP 3.6% 2,402,238 +1290% 0% $15,806,726
PRICE T ROWE ASSOCIATES INC /MD/ 3% 1,993,958 +11% 0% $13,121,000
BlackRock, Inc. 2.2% 1,451,706 +113% 0% $9,552,225
MARSHALL WACE, LLP 1.1% 711,875 +162% 0% $4,684,136
Blue Owl Capital Holdings LP 1% 665,000 +21% 1.4% $4,375,700
GEODE CAPITAL MANAGEMENT, LLC 0.94% 618,074 +20% 0% $4,068,348
Occam Crest Management LP 0.75% 498,498 0% 2.4% $3,280,117
MORGAN STANLEY 0.74% 489,617 +66% 0% $3,221,679
GOLDMAN SACHS GROUP INC 0.48% 318,809 0% $2,097,763
BURKEHILL GLOBAL MANAGEMENT, LP 0.45% 300,000 0% 0.13% $1,974,000
SOUTHPORT MANAGEMENT, L.L.C. 0.42% 277,501 +1.8% 6.4% $1,825,957
Diametric Capital, LP 0.37% 246,857 -2.1% 0.44% $1,624,319
BARCLAYS PLC 0.35% 230,726 +943% 0% $1,518,177
DCF Advisers, LLC 0.33% 215,000 0.47% $1,414,700
BANK OF AMERICA CORP /DE/ 0.32% 214,341 +390% 0% $1,410,364
TWO SIGMA INVESTMENTS, LP 0.31% 207,155 +92% 0% $1,363,080
UBS Group AG 0.29% 190,333 +51% 0% $1,252,391
Qube Research & Technologies Ltd 0.25% 165,875 0% $1,091,458
RENAISSANCE TECHNOLOGIES LLC 0.23% 152,300 +335% 0% $1,002,134
683 Capital Management, LLC 0.23% 150,697 0.08% $991,586
Woodline Partners LP 0.23% 150,000 0% 0% $987,000

Institutional Holders of Immuneering Corp - Class A common stock, par value $0.001 per share (IMRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 31,745,075 $208,863,999 +$18,230,258 $6.58 86
2025 Q3 26,061,962 $182,434,908 +$152,080,293 $7.00 69
2025 Q2 3,829,641 $12,906,115 -$684,732 $3.37 39
2025 Q1 4,498,583 $6,835,562 +$160,625 $1.52 34
2024 Q4 4,238,711 $9,324,244 -$178,796 $2.20 41
2024 Q3 4,355,017 $10,869,922 -$7,529,696 $2.49 38
2024 Q2 9,594,278 $12,279,759 -$9,114,134 $1.28 57
2024 Q1 11,871,050 $34,309,079 -$12,746,356 $2.89 50
2023 Q4 16,130,676 $118,561,919 -$6,044,147 $7.35 52
2023 Q3 16,940,765 $130,107,793 -$5,076,687 $7.68 52
2023 Q2 17,269,962 $175,881,466 +$55,986,602 $10.14 49
2023 Q1 11,823,558 $114,882,649 +$3,734,772 $9.71 34
2022 Q4 11,722,865 $56,864,840 -$4,241,513 $4.85 32
2022 Q3 12,063,607 $172,475,348 -$5,229,083 $14.32 30
2022 Q2 12,148,741 $65,706,270 -$8,960,781 $5.41 33
2022 Q1 13,611,716 $88,116,760 -$3,464,272 $6.47 49
2021 Q4 12,489,185 $199,826,000 +$5,452,786 $16.17 36
2021 Q3 12,105,226 $316,421,451 +$316,421,451 $26.55 38